Cardiol Therapeutics Inc.
$1.51
▲
0.71%
2026-04-21 06:13:00
www.cardiolrx.com
NCM: CRDL
Explore Cardiol Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$230.46 M
Current Price
$1.51
52W High / Low
$2.17 / $1.23
Stock P/E
—
Book Value
$0.08
Dividend Yield
—
ROCE
-162.05%
ROE
-1.59%
Face Value
—
EPS
$-0.28
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
—
Beta
0.43
Debt / Equity
0.7
Current Ratio
4.16
Quick Ratio
4.16
Forward P/E
-8.11
Price / Sales
—
Enterprise Value
$133.09 M
EV / EBITDA
-3.88
EV / Revenue
—
Rating
Strong Buy
Target Price
$7.44
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Collegium Pharmaceutical, Inc. | $34.31 | 17.33 | $1.09 B | — | 14.67% | 23.7% | $50.79 / $25.86 | $9.51 |
| 2. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 3. | Evolus, Inc. | $5.08 | — | $330.5 M | — | -24.97% | 587.36% | $12.28 / $3.86 | $-0.35 |
| 4. | Elanco Animal Health Incorporated | $22.34 | — | $11.2 B | — | 2.14% | -3.67% | $27.72 / $8.02 | $13.17 |
| 5. | Sunshine Biopharma, Inc. | $1.02 | — | $5.05 M | — | -23.97% | -25.68% | $2.43 / $0.95 | $5.31 |
| 6. | Eton Pharmaceuticals, Inc. | $25.28 | — | $683.2 M | — | -1.57% | -18.19% | $27.29 / $13.09 | $0.97 |
| 7. | Viatris Inc. | $14.78 | — | $17.2 B | 3.23% | 0.84% | -21.08% | $16.47 / $7.39 | $12.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.03 M | -10.18 M | -7.68 M | -8.43 M | -9.99 M | — |
| Net Profit | -7.21 M | -9.96 M | -8.35 M | -8.29 M | -8.18 M | — |
| EPS in Rs | -0.06 | -0.09 | -0.07 | -0.07 | -0.07 | -0.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -34.32 M | -40.28 M | -29.79 M | -41.34 M |
| Net Profit | -33.82 M | -36.68 M | -28.13 M | -30.93 M |
| EPS in Rs | -0.3 | -0.33 | -0.25 | -0.28 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 23.62 M | 31.86 M | 36.7 M | 62.03 M |
| Total Liabilities | 5.74 M | 7.14 M | 8.45 M | 9.83 M |
| Equity | 17.88 M | 24.73 M | 28.25 M | 52.2 M |
| Current Assets | 23.5 M | 31.67 M | 36.15 M | 61.44 M |
| Current Liabilities | 5.66 M | 7.01 M | 8.3 M | 9.8 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -23.85 M | -25.06 M | -25.18 M | -27.22 M |
| Investing CF | -0.02 M | -0.02 M | -0.06 M | -0.07 M |
| Financing CF | 15.54 M | 18.84 M | -0.06 M | -0.05 M |
| Free CF | -23.88 M | -25.08 M | -25.24 M | -27.3 M |
| Capex | -0.02 M | -0.02 M | -0.06 M | -0.07 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -30.39% | 9.06% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.